107 related articles for article (PubMed ID: 7132958)
1. Ames test and antitumor activity of 1-(X-phenyl)-3,3-dialkyltriazenes. Quantitative structure-activity studies based upon molecular shape analysis.
Hopfinger AJ; Potenzone R
Mol Pharmacol; 1982 Jan; 21(1):187-95. PubMed ID: 7132958
[TBL] [Abstract][Full Text] [Related]
2. Ames test of 1-(X-phenyl)-3,3-dialkyltriazenes. A quantitative structure-activity study.
Venger BH; Hansch C; Hatheway GJ; Amrein YU
J Med Chem; 1979 May; 22(5):473-6. PubMed ID: 379331
[TBL] [Abstract][Full Text] [Related]
3. Mutagenicity of dimethyl heteroaromatic triazenes in the Ames test: the role of hydrophobicity and electronic effects.
Shusterman AJ; Debnath AK; Hansch C; Horn GW; Fronczek FR; Greene AC; Watkins SF
Mol Pharmacol; 1989 Dec; 36(6):939-44. PubMed ID: 2601689
[TBL] [Abstract][Full Text] [Related]
4. Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 2. On the role of correlation analysis in decision making in drug modification. Toxicity quantitative structure-activity relationships of 1-(X-phenyl)-3,3-dialkyltriazenes in mice.
Hansch C; Hatheway GJ; Quinn FR; Greenberg N
J Med Chem; 1978 Jun; 21(6):574-7. PubMed ID: 671454
[TBL] [Abstract][Full Text] [Related]
5. QSAR analyses of 3-(4-benzylpiperidin-1-yl)-N-phenylpropylamine derivatives as potent CCR5 antagonists.
Roy K; Leonard JT
J Chem Inf Model; 2005; 45(5):1352-68. PubMed ID: 16180912
[TBL] [Abstract][Full Text] [Related]
6. Anticancer activity of selected phenolic compounds: QSAR studies using ridge regression and neural networks.
Nandi S; Vracko M; Bagchi MC
Chem Biol Drug Des; 2007 Nov; 70(5):424-36. PubMed ID: 17949360
[TBL] [Abstract][Full Text] [Related]
7. Three new consensus QSAR models for the prediction of Ames genotoxicity.
Votano JR; Parham M; Hall LH; Kier LB; Oloff S; Tropsha A; Xie Q; Tong W
Mutagenesis; 2004 Sep; 19(5):365-77. PubMed ID: 15388809
[TBL] [Abstract][Full Text] [Related]
8. Mutagenic potency of food-derived heterocyclic amines.
Felton JS; Knize MG; Wu RW; Colvin ME; Hatch FT; Malfatti MA
Mutat Res; 2007 Mar; 616(1-2):90-4. PubMed ID: 17161439
[TBL] [Abstract][Full Text] [Related]
9. A QSAR for the mutagenic potencies of twelve 2-amino-trimethylimidazopyridine isomers: structural, quantum chemical, and hydropathic factors.
Knize MG; Hatch FT; Tanga MJ; Lau EY; Colvin ME
Environ Mol Mutagen; 2006 Mar; 47(2):132-46. PubMed ID: 16258923
[TBL] [Abstract][Full Text] [Related]
10. QSAR models to predict mutagenicity of acrylates, methacrylates and alpha,beta-unsaturated carbonyl compounds.
Pérez-Garrido A; Helguera AM; Rodríguez FG; Cordeiro MN
Dent Mater; 2010 May; 26(5):397-415. PubMed ID: 20122717
[TBL] [Abstract][Full Text] [Related]
11. Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.
Hatheway GJ; Hansch C; Kim KH; Milstein SR; Schmidt CL; Smith RN; Quinn FR
J Med Chem; 1978 Jun; 21(6):563-74. PubMed ID: 671453
[TBL] [Abstract][Full Text] [Related]
12. SOS chromotest results in a broader context: empirical relationships between genotoxic potency, mutagenic potency, and carcinogenic potency.
White PA; Rasmussen JB
Environ Mol Mutagen; 1996; 27(4):270-305. PubMed ID: 8665872
[TBL] [Abstract][Full Text] [Related]
13. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.
Mor M; Rivara S; Lodola A; Plazzi PV; Tarzia G; Duranti A; Tontini A; Piersanti G; Kathuria S; Piomelli D
J Med Chem; 2004 Oct; 47(21):4998-5008. PubMed ID: 15456244
[TBL] [Abstract][Full Text] [Related]
14. Structural bioinformatics and QSAR analysis applied to the acetylcholinesterase and bispyridinium aldoximes.
Mager PP; Weber A
Drug Des Discov; 2003; 18(4):127-50. PubMed ID: 15553925
[TBL] [Abstract][Full Text] [Related]
15. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic QSAR of aromatic amines: new models for discriminating between homocyclic mutagens and nonmutagens, and validation of models for carcinogens.
Benigni R; Bossa C; Netzeva T; Rodomonte A; Tsakovska I
Environ Mol Mutagen; 2007 Dec; 48(9):754-71. PubMed ID: 18008355
[TBL] [Abstract][Full Text] [Related]
17. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Pharmacogenetics; 1999 Aug; 9(4):477-89. PubMed ID: 10780267
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, X-ray crystal structures, stabilities, and in vitro cytotoxic activities of new heteroarylacrylonitriles.
Saczewski F; Reszka P; Gdaniec M; Grünert R; Bednarski PJ
J Med Chem; 2004 Jun; 47(13):3438-49. PubMed ID: 15189040
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity considerations and in vitro approaches to assess the genotoxicity of 19 methane-, benzene- and toluenesulfonic acid esters.
Glowienke S; Frieauff W; Allmendinger T; Martus HJ; Suter W; Mueller L
Mutat Res; 2005 Mar; 581(1-2):23-34. PubMed ID: 15725602
[TBL] [Abstract][Full Text] [Related]
20. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
